New contender takes on blockbuster wegovy in Head-to-Head weight loss showdown
NCT ID NCT07150975
Summary
This study aims to see if a new injectable drug called GZR18 works as well or better than the established medication Wegovy (semaglutide) for weight management. It will involve 420 adults who are overweight or have obesity, some with and some without type 2 diabetes. Participants will be randomly assigned to receive weekly injections of either GZR18 or Wegovy for one year to compare weight loss results and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY/OVERWEIGHT IN ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.